Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (Nasdaq: COGT) generates frequent news flow as a biotechnology company developing precision therapies for genetically defined diseases. Its updates often center on the clinical and regulatory progress of bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V and other KIT exon 17 mutations associated with systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST).
News for COGT commonly includes clinical trial milestones from the pivotal SUMMIT, APEX and PEAK studies. SUMMIT evaluates bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM), APEX in Advanced Systemic Mastocytosis (AdvSM), and PEAK in imatinib-resistant or intolerant GIST in combination with sunitinib. Press releases have highlighted positive top-line results, detailed efficacy and safety data, and plans for New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.
Investors and followers of COGT can also expect regulatory and designation announcements, such as Breakthrough Therapy Designation for bezuclastinib in specific NonAdvSM populations, as well as updates on Expanded Access Programs for eligible GIST and SM patients. Financial and corporate news appears regularly, including equity and convertible note offerings, cash runway commentary, and participation in major healthcare investor conferences like the J.P. Morgan Healthcare Conference and the Jefferies Global Healthcare Conference.
In addition, Cogent issues news on its early-stage pipeline, including a selective and potent FGFR2/3 inhibitor in Phase 1/2 and discovery programs targeting ErbB2, PI3Kα, KRAS and JAK2. For readers tracking COGT, this news page provides an organized view of trial readouts, regulatory plans, financing events and scientific presentations that shape the company’s development trajectory. Bookmark this feed to monitor Cogent’s ongoing disclosures about its precision oncology and hematology programs.
Summary not available.
Summary not available.
Cogent Biosciences (COGT) announced significant advancements in its pipeline during the AACR 2023 Annual Meeting. The company presented updated preclinical data on a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor targeting key mutations, showcasing improved potency and selectivity. Additionally, the company initiated Part 2 of its APEX trial for bezuclastinib, dosing 150 mg daily in Advanced Systemic Mastocytosis (AdvSM). This second phase aims to enroll 65 patients and potentially support regulatory submissions upon success. The enhanced formulation of bezuclastinib is expected to yield better clinical exposure compared to the prior dosage. Upcoming clinical data updates from both APEX and other trials are anticipated in late 2023.
Cogent Biosciences, Inc. (Nasdaq: COGT) has announced its participation in two upcoming virtual investor conferences. The first is the 22nd Annual Needham Healthcare Conference scheduled for April 19, 2023, at 2:15 p.m. ET. The second event is the Stifel 2023 Targeted Oncology Days on April 25, 2023, at 12:30 p.m. ET. Investors can access live webcasts of these conferences on Cogent's Investors & Media page, with replays available within two hours after each event, lasting for 30 days. Cogent, based in Waltham, MA, and Boulder, CO, focuses on precision therapies for genetically defined diseases, with bezuclastinib being its advanced clinical program targeting specific mutations linked to serious conditions like systemic mastocytosis and gastrointestinal stromal tumors.
Cogent Biosciences (Nasdaq: COGT) announced significant developments in Q4 2022, including the initiation of the Phase 3 PEAK trial for gastrointestinal stromal tumors (GIST) and positive clinical data for bezuclastinib in systemic mastocytosis. Cash reserves stood at $259.3 million, sufficient to fund operations until 2025. The company aims to advance multiple clinical programs in 2023, with key data expected from the Phase 2 SUMMIT trial for NonAdvSM and updated results from Phase 3 PEAK. However, the net loss grew to $39.6 million in Q4 2022, and R&D expenses increased significantly to $36.7 million.
Cogent Biosciences (Nasdaq: COGT) announced its participation in two upcoming investor conferences in February 2023. Andrew Robbins, President and CEO, will present at the Guggenheim Healthcare Talks Idea Forum Oncology Day on February 8 at 10:10 a.m. ET, and the SVB Securities Global Biopharma Conference on February 14 at 9:20 a.m. ET. Interested investors can access live webcasts of these events on the Investors & Media page of Cogent's website, with replays available for 30 days post-event. Cogent focuses on precision therapies for genetically defined diseases, including bezuclastinib for systemic mastocytosis and advanced gastrointestinal stromal tumors.
Cogent Biosciences (COGT) is advancing its portfolio in 2023 with key milestones. The company is set to announce mid-year results from its Phase 2 APEX trial in Advanced Systemic Mastocytosis (AdvSM) and initial data from the Phase 2 SUMMIT trial in Non-Advanced SM later this year. Also, bezuclastinib's clinical progress includes updates from the Phase 3 PEAK trial for Gastrointestinal Stromal Tumors (GIST), expanding to over 100 global sites. Cogent aims to enhance its pipeline with new targeted cancer therapies, anticipating a total of five distinct programs by the end of 2023.
Cogent Biosciences (COGT) announced that CEO Andrew Robbins will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 7:30 a.m. PT. A live webcast will be accessible on the company’s website, with a replay available post-event for 30 days. Cogent focuses on precision therapies for genetically defined diseases, notably developing bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation. The company aims to address serious diseases like systemic mastocytosis and advanced gastrointestinal stromal tumors.
Cogent Biosciences (COGT) reported positive updated data from its ongoing Phase 2 APEX clinical trial for the TKI D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). Key findings include an 89% overall response rate (ORR) in TKI-therapy naïve patients and a 73% ORR in all evaluable patients after 27 weeks of median follow-up. Safety results show no cognitive side effects or intracranial bleeding events. Cogent will continue patient enrollment in APEX and other trials for broader indications, with updates planned for 2023.
Cogent Biosciences (Nasdaq: COGT) is set to host an investor webcast on December 12, 2022, at 8:00 a.m. ET, presenting updated clinical data from its Phase 2 APEX trial of bezuclastinib in patients with Advanced Systemic Mastocytosis. The event will feature insights from Cogent’s President and CEO Andrew Robbins and Dr. Daniel J. DeAngelo from the Dana-Farber Cancer Institute. This data presentation is occurring during the 64th ASH Annual Meeting. A live webcast will be accessible on Cogent's website.